267 related articles for article (PubMed ID: 34920905)
1. Histopathologic diagnosis of endometrial precancers: Updates and future directions.
Chen H; Strickland AL; Castrillon DH
Semin Diagn Pathol; 2022 May; 39(3):137-147. PubMed ID: 34920905
[TBL] [Abstract][Full Text] [Related]
2. Reliable Identification of Endometrial Precancers Through Combined Pax2, β-Catenin, and Pten Immunohistochemistry.
Aguilar M; Chen H; Rivera-Colon G; Niu S; Carrick K; Gwin K; Cuevas IC; Sahoo SS; Li HD; Zhang S; Zheng W; Lucas E; Castrillon DH
Am J Surg Pathol; 2022 Mar; 46(3):404-414. PubMed ID: 34545858
[TBL] [Abstract][Full Text] [Related]
3. Utility of a PAX2, PTEN, and β-catenin Panel in the Diagnosis of Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia in Endometrial Polyps.
Lucas E; Niu S; Aguilar M; Molberg K; Carrick K; Rivera-Colon G; Gwin K; Wang Y; Zheng W; Castrillon DH; Chen H
Am J Surg Pathol; 2023 Sep; 47(9):1019-1026. PubMed ID: 37314146
[TBL] [Abstract][Full Text] [Related]
4. Management of endometrial precancers.
Trimble CL; Method M; Leitao M; Lu K; Ioffe O; Hampton M; Higgins R; Zaino R; Mutter GL;
Obstet Gynecol; 2012 Nov; 120(5):1160-75. PubMed ID: 23090535
[TBL] [Abstract][Full Text] [Related]
5. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer.
Monte NM; Webster KA; Neuberg D; Dressler GR; Mutter GL
Cancer Res; 2010 Aug; 70(15):6225-32. PubMed ID: 20631067
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in the Diagnosis of Endometrial Precancers. Molecular Characteristics, Candidate Immunohistochemical Markers, and Promising Results of Three-Marker Panel: Current Status and Future Directions.
Niu S; Molberg K; Castrillon DH; Lucas E; Chen H
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539494
[TBL] [Abstract][Full Text] [Related]
7. β-catenin, Pax2, and Pten Panel Identifies Precancers Among Histologically Subdiagnostic Endometrial Lesions.
Aguilar M; Chen H; Sahoo SS; Zheng W; Grubman J; SoRelle JA; Lucas E; Castrillon DH
Am J Surg Pathol; 2023 May; 47(5):618-629. PubMed ID: 36939046
[TBL] [Abstract][Full Text] [Related]
8. Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Campanino MR; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Mar; 98(3):275-286. PubMed ID: 30511743
[TBL] [Abstract][Full Text] [Related]
9. Specific Biomarker Expression Patterns in the Diagnosis of Residual and Recurrent Endometrial Precancers After Progestin Treatment: A Longitudinal Study.
Chen H; Lucas E; Strickland AL; Carrick K; Gwin K; Castrillon DH; Rivera-Colon G; Niu S; Molberg KH; Zheng W
Am J Surg Pathol; 2020 Oct; 44(10):1429-1439. PubMed ID: 32931681
[TBL] [Abstract][Full Text] [Related]
10. Nuclear expression of β-catenin in endometrial hyperplasia as marker of premalignancy.
Travaglino A; Raffone A; Saccone G; Mascolo M; D'Alessandro P; Arduino B; Mollo A; Insabato L; Zullo F
APMIS; 2019 Nov; 127(11):699-709. PubMed ID: 31403731
[TBL] [Abstract][Full Text] [Related]
11. [Morphological diagnosis of endometrial intraepithelial neoplasia and expression of PTEN].
Zhou WX; Liang ZY; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2009 Jun; 38(6):393-6. PubMed ID: 19781346
[TBL] [Abstract][Full Text] [Related]
12. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.
Mutter GL; Lin MC; Fitzgerald JT; Kum JB; Baak JP; Lees JA; Weng LP; Eng C
J Natl Cancer Inst; 2000 Jun; 92(11):924-30. PubMed ID: 10841828
[TBL] [Abstract][Full Text] [Related]
13. New concepts for an old problem: the diagnosis of endometrial hyperplasia.
Sanderson PA; Critchley HO; Williams AR; Arends MJ; Saunders PT
Hum Reprod Update; 2017 Mar; 23(2):232-254. PubMed ID: 27920066
[TBL] [Abstract][Full Text] [Related]
14. Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia.
Quddus MR; Ologun BA; Sung CJ; Steinhoff MM; Lawrence WD
Int J Gynecol Pathol; 2009 Sep; 28(5):471-6. PubMed ID: 19696618
[TBL] [Abstract][Full Text] [Related]
15. BCL-2 and PAX2 Expressions in EIN which Had Been Previously Diagnosed as Non-Atypical Hyperplasia.
Trabzonlu L; Muezzinoglu B; Corakci A
Pathol Oncol Res; 2019 Apr; 25(2):471-476. PubMed ID: 29270778
[TBL] [Abstract][Full Text] [Related]
16. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
17. Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma.
Xiong Y; Xiong YY; Zhou YF
Eur J Gynaecol Oncol; 2010; 31(2):160-4. PubMed ID: 20527231
[TBL] [Abstract][Full Text] [Related]
18. Endometrial glandular dysplasia and endometrial intraepithelial neoplasia.
Yi X; Zheng W
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):20-5. PubMed ID: 18197001
[TBL] [Abstract][Full Text] [Related]
19. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group.
Mutter GL
Gynecol Oncol; 2000 Mar; 76(3):287-90. PubMed ID: 10684697
[TBL] [Abstract][Full Text] [Related]
20. Management of abnormal uterine bleeding and the pathology of endometrial hyperplasia.
Espindola D; Kennedy KA; Fischer EG
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):717-37, ix. PubMed ID: 18061866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
